[1. Udani SM and Murray PT. The use of renal replacement therapy in acute decompensated heart failure. Semin Dial. 2009; 22: 173–179.10.1111/j.1525-139X.2008.00542.x]Search in Google Scholar
[2. Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med. 2014; 4: 176–188.10.1159/000366168]Search in Google Scholar
[3. Forman DE, Butler J, Wang Y, Abraham WT et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43: 61–67.10.1016/j.jacc.2003.07.031]Search in Google Scholar
[4. Kazory A. Cardiorenal syndrome: ultrafiltration therapy for heart failure–trials and tribulations. Clin J Am Soc Nephrol. 2013; 8: 1816–1828.10.2215/CJN.02910313]Search in Google Scholar
[5. Bart BA, Boyle A, Bank AJ, Anand I, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005; 46: 2043–2046.10.1016/j.jacc.2005.05.098]Search in Google Scholar
[6. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, et al. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007; 49: 675–683.10.1016/j.jacc.2006.07.073]Search in Google Scholar
[7. Marenzi G, Muratori M, Cosentino ER, Rinaldi ER, et al. Continuous ultrafiltration for congestive heart failure: the CUORE trial. J Card Fail. 2014; 20: 9–17.10.1016/j.cardfail.2013.11.004]Search in Google Scholar
[8. Chen HY, Chou KJ, Fang HC, Chen CL, et al. Effect of ultrafiltration versus intravenous furosemide for decompensated heart failure in cardiorenal syndrome: a systematic review with meta-analysis of randomized controlled trials. Nephron. 2015; 129(3): 189–96.10.1159/000371447]Search in Google Scholar
[9. Krishnamoorthy A and Felker GM. Fluid removal in acute heart failure: diuretics versus devices. Curr Op Crit Care. 2014; 20: 478–483.10.1097/MCC.0000000000000134]Search in Google Scholar
[10. Nakayama M. Nonuremic indication for peritoneal dialysis for refractory heart failure in cardiorenal syndrome type II: review and perspective. Perit Dial Int. 2013; 33: 8–14.10.3747/pdi.2012.00014]Search in Google Scholar
[11. Bertoli SV, Musetti C, Ciurlino D, Basile C, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int. 2014; 34: 64–70.10.3747/pdi.2012.00290]Search in Google Scholar
[12. Courivaud C, Kazory A, Crépin T, Azar R, et al. Peritoneal dialysis reduces the number of hospitalizetion days in heart failure patients refractory to diuretics. Perit Dial Int 2014; 34: 100–108.10.3747/pdi.2012.00149]Search in Google Scholar
[13. Lu R, Muciño-Bermejo MJ, Ribeiro LC, Tonini E, et al. Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med. 2015; 5: 145–156.10.1159/000380915]Search in Google Scholar
[14. Puttagunta H and Holt SG. Peritoneal Dialysis for Heart Failure. Perit Dial Int. 2015; 35: 645–649.10.3747/pdi.2014.00340]Search in Google Scholar
[15. Kazory A. Peritoneal dialysis for chronic cardiorenal syndrome: Lessons learned from ultrafiltration trials. World J Cardiol. 2015; 26: 392–396.10.4330/wjc.v7.i7.392]Search in Google Scholar